Xeris Biopharma Holdings (XERS) Enterprise Value (2020 - 2025)
Xeris Biopharma Holdings (XERS) has disclosed Enterprise Value for 6 consecutive years, with -$111.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 54.98% year-over-year to -$111.0 million, compared with a TTM value of -$111.0 million through Dec 2025, down 54.98%, and an annual FY2025 reading of -$111.0 million, down 54.98% over the prior year.
- Enterprise Value was -$111.0 million for Q4 2025 at Xeris Biopharma Holdings, down from -$91.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$58.4 million in Q1 2025 and bottomed at -$132.1 million in Q1 2022.
- Average Enterprise Value over 5 years is -$88.6 million, with a median of -$89.5 million recorded in 2024.
- The sharpest move saw Enterprise Value crashed 145.43% in 2021, then soared 40.6% in 2023.
- Year by year, Enterprise Value stood at -$102.4 million in 2021, then dropped by 19.07% to -$122.0 million in 2022, then skyrocketed by 40.6% to -$72.5 million in 2023, then increased by 1.15% to -$71.6 million in 2024, then crashed by 54.98% to -$111.0 million in 2025.
- Business Quant data shows Enterprise Value for XERS at -$111.0 million in Q4 2025, -$91.6 million in Q3 2025, and -$59.3 million in Q2 2025.